Fig. 1.

Titers in NY-ESO-1–seropositive patients from MSKCC. Reciprocal antibody titers to NY-ESO-1 throughout CTLA-4 blockade treatment in patients experiencing clinical benefit (closed symbols, Left; n = 11) or no clinical benefit (open symbols, Right; n = 10) among 99 patients treated with ipilimumab at MSKCC. The remaining 78 patients did not show significant Ab reactivity against NY-ESO-1 at any time point tested and were considered seronegative (i.e., titers <100). Each symbol represents a patient (Right) at baseline, week 7, and week 12 or 24.